Startups · AI

Principal Scientist, mRNA-tLNP Analytical Development

Kernal Biologics · Boston, MA · On-site

← All jobs
About Kernal Biologics

Kernal biologics is an onco-selective mRNA therapeutics company located in Cambridge, MA. Backed by Y Combinator.

About the role

The Principal Scientist, Analytical Development at Kernal Biologics, will report to the Director of Drug Product Development and will lead the design, development, and execution of analytical methods to support the company’s mRNA platform for in vivo CAR-T programs.

What they're looking for

  • PhD (6+ years), MS (8+ years), or BS (12+ years) in Chemistry, Biochemistry, Biology, Pharmaceutical Sciences, or a related field, with relevant industry experience
  • Strategic understanding of characterization approaches for mRNA, LNPs, biologics, monoclonal antibodies, and related modalities and bioconjugations
  • Experience providing technical oversight of CRO/CDMO analytical activities, including ICH-compliant stability programs and GMP testing
  • Experience with cell-based potency assay development, qualification, and troubleshooting is highly desirable
  • Strong knowledge of CMC regulatory expectations and analytical requirements for global regulatory submissions
More about this role

Kernal Bio is a venture-backed therapeutics company engineering cells inside the body using AI-designed, selective mRNA and targeted lipid nanoparticle (tLNP) technology. By developing in vivo CAR-T therapies, Kernal Bio is advancing precision treatments for autoimmune diseases and blood cancers.

The company was founded by experts from MIT, Harvard, Merck, and Bristol Myers Squibb. Its leadership team brings a track record that includes three FDA-approved therapies and more than 120 patents. With support from leading investors—including Hummingbird Ventures, Amgen Ventures, Y Combinator, and HBM—Kernal Bio is transforming the future of cell therapy design and delivery.

The Principal Scientist, Analytical Development at Kernal Biologics, will report to the Director of Drug Product Development and will lead the design, development, and execution of analytical methods to support the company’s mRNA platform for in vivo CAR-T programs. This role focuses on biophysical characterization and in vitro assay development for early-stage programs, with particular emphasis on antibody-targeted LNPs — including characterization of the antibody–lipid conjugates and the ligand-decorated particles...

Read the full posting on Kernal Biologics's site ↗

R&D

Build your edge while you search

Free tools for founders and investors, plus VC Unfiltered, our take on startups, venture and the people who build them.